These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 24462284

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, Dumont F, Brigand C, Passot G, Glehen O, RENAPE Network.
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
    Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B.
    Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
    [Abstract] [Full Text] [Related]

  • 25. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
    Sugarbaker PH.
    Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M.
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA, Fisher OM, Rebolledo BJ, Valle SJ, Alzahrani N, Liauw W, Morris DL.
    Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M.
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [Abstract] [Full Text] [Related]

  • 36. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, Glehen O, Sardi A, Barrios P, Quénet F, Villeneuve L, Gómez-Portilla A, de Hingh I, Ceelen W, Pelz JOW, Piso P, González-Moreno S, Van Der Speeten K, Deraco M, Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE).
    JAMA Surg; 2021 Mar 01; 156(3):e206363. PubMed ID: 33502455
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
    Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG.
    Eur J Surg Oncol; 2012 Oct 01; 38(10):969-76. PubMed ID: 22763244
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S, Baratti D, Hutanu I, Gavazzi C, Morelli D, Iusco DR, Grassi A, Bonomi S, Virzì S, Haeusler E, Deraco M.
    Eur J Surg Oncol; 2015 Aug 01; 41(8):1097-105. PubMed ID: 26026742
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.